Is NovoCure (NVCR) Undervalued On TTFields Validation And Board Change?
NovoCure (NVCR) moved back into the spotlight after long-serving director Timothy Scannell retired from the board on 2 September 2026, just as its TTFields therapy gained validation across several new cancer indications.
Against that backdrop, NovoCure’s recent governance change and TTFields milestones land after a mixed stretch for investors, with the share price delivering a 23.86% year to date gain but a 5 year total shareholder return that has fallen 86.01%. This suggests near term momentum is rebuilding while long term holders remain deeply under water.
Compare NovoCure’s rebound and valuation reset with a curated group of oncology and high-growth healthcare names by scanning the 38 healthcare AI stocks for your next research candidates.
That rebound raises a blunt question for NovoCure. Are investors finally reassessing the TTFields business after fresh clinical validation, or is this just sentiment snapping back after a brutal five year reset that leaves the current valuation in focus?
Most Popular Narrative: 38% Undervalued
At a last close of $16.25, the most followed narrative pegs NovoCure’s fair value at $26.07. This creates a wide gap that puts its TTFields rollout, reimbursement wins, and earnings path under the microscope.
Validation of TTFields therapy in multiple new indications, such as pancreatic cancer (PANOVA-3) and brain metastases from non-small cell lung cancer (METIS), positions NovoCure for potential regulatory approvals and large market expansion beginning in 2026, likely driving topline revenue growth as global cancer incidence rises in the aging population.
See why 11 investors see NovoCure as 38% undervalued.
Result: Fair Value of $26.07 (UNDERVALUED)
Still, the NovoCure narrative hinges on wider TTFields adoption and smoother reimbursement, so any slowdown in prescriptions or setbacks in payer coverage could quickly challenge that 38% undervalued story.
Find out about the key risks to this NovoCure narrative.
Next Steps
With sentiment split between a harsh five year decline and fresh optimism around TTFields, you should weigh both sides quickly and on your own terms. Start by reviewing the 3 key rewards and 1 important warning sign.
Looking for more NovoCure-sized opportunities?
If NovoCure has sharpened your focus on risk and reward, do not stop there. Broaden your watchlist and test new ideas before the next move.
- Target potential mispricings by scanning companies flagged as 30 high quality undervalued stocks that pair quality fundamentals with discounted share prices.
- Build a steadier income stream by reviewing 7 dividend fortresses that combine higher yields with a focus on durability.
- Strengthen portfolio resilience by filtering for businesses in the list of solid balance sheet and fundamentals (23 results) that emphasise cash, low leverage, and financial flexibility.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com